Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical Infectious Diseases

• Publication date

  1999-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/515223PMID 10825058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease.

  1997cited by this paper
• Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus.

  1997cited by this paper
• Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients

  1997cited by this paper
• Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS

  1996cited by this paper
• Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival

  1996cited by this paper
• Quantitation Of Human Cytomegalovirus DNA From Peripheral Blood Cells Of Human Immunodeficiency Virus-Infected Patients Could Predict Cytomegalovirus Retinitis

  1995cited by this paper
• Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.

  1995cited by this paper
• Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes

  1995cited by this paper
• Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients

  1994cited by this paper
• Polymerase chain reaction detection of cytomegalovirus DNA in peripheral blood leukocytes as a predictor of cytomegalovirus disease in HIV‐infected patients

  1993cited by this paper
• Human CMV infection of the CNS: concordance between PCR detection in CSF and pathological examination.

  1993cited by this paper
• Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS

  1990cited by this paper
• Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients.

  1988cited by this paper

• Anti-cytomegalovirus preemptive therapy to prevent cytomegalovirus disease in HIV-infected patients: a systematic review

  2023cites this paper
• Efficacy and safety of preemptive therapy for cytomegalovirus end-organ disease in people living with HIV: a systematic review and meta-analysis

  2023cites this paper
• Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients

  2023cites this paper
• Diagnostic Utility of Quantitative Plasma Cytomegalovirus DNA PCR for Cytomegalovirus End-Organ Diseases in Patients With HIV-1 Infection

  2015cites this paper
• Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia

  2015cites this paper
• Fatal cytomegalovirus gastrointestinal disease in an infant with Wiskott-Aldrich syndrome.

  2008cites this paper
• Medical treatment of viral pneumonia including SARS in immunocompetent adult

  2004cites this paper
• Opportunistic Infections

  2003cites this paper
• Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy

  2000cites this paper